Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisi
There's no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to receive treatment, whilst also reducing risks like
BeiGene is looking increasingly like it will become the leading challenger to AbbVie and Johnson & Johnson's market-leading BTK inhibitor Imbruvica for cancer, after besting its rival i
Australian biotech Immutep's LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at l
Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.
Precision medicine is oft spoken about these days, as it is finally addressing the elephant in the room: one size – or, more appropriately, one dose – does not fit all.